GLP-1 Medications for Quitting Vaping: Ozempic, Wegovy, Mounjaro, and the 2026 Trial Data

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda) — went from diabetes drugs to weight loss drugs to a serious candidate cessation pharmacotherapy in under five years. As of June 2026, multiple Phase 2 and Phase 3 trials are actively recruiting and several published trials show that GLP-1s reduce nicotine cravings, lower self-reported cigarette and vape consumption, and may improve abstinence outcomes — though no GLP-1 is FDA-approved for vaping cessation and the current trial evidence base is small. This guide walks through what the research currently shows, the mechanism, the off-label use landscape, and where GLP-1s fit (and don’t fit) in a 2026 vaping cessation plan.

For the broader pharmacotherapy landscape, see our prescription drugs overview and Chantix alternatives guide. For the underlying GLP-1-and-smoking research we’ve covered before, see our Ozempic for quitting smoking guide.

What the Current Trial Evidence Shows

The 2026 trial landscape includes several parallel research lines.

Published narrative review (Annals of Medicine and Surgery, March 2026) concluded that GLP-1 receptor agonists — particularly exenatide and semaglutide — exhibit promising neurobehavioral and metabolic effects in smoking cessation. The review pulled together preclinical and clinical data showing that GLP-1s reduce nicotine self-administration in animal models and reduce craving and consumption in early human trials.

Springer Endocrine review (2026) assessed GLP-1 receptor agonists as “therapeutic promise beyond glycemia” for smoking cessation, with the strongest case in patients with comorbid type 2 diabetes — where the GLP-1 is already indicated and the cessation benefit becomes a secondary upside.

Active Phase 2 trial (Power): Semaglutide is being studied specifically for tobacco use disorder. Trial uses semaglutide 2.4 mg weekly subcutaneously and tracks nicotine craving and cigarette consumption changes.

NCT07059377 (clinicaltrials.gov): Single-center parallel-group RCT randomizing 46 male adults with type 2 diabetes and Fagerström Test for Nicotine Dependence scores ≥4 to a GLP-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor for 24 weeks. Reports cessation outcomes.

Post-cessation weight-gain RCT (PubMed 40554081): Randomizes 177 treatment-seeking smokers with overweight/obesity to once-weekly semaglutide 2.4 mg or placebo for 28 weeks, tracking both cessation and weight outcomes.

The key gap: there are no published Phase 3 trials of GLP-1s for vaping cessation specifically. The mechanistic case for translation from smoking to vaping is solid (both involve the same nicotinic receptor downregulation and dopamine-reward circuit) but the direct evidence base for vaping is currently thin.

The Mechanism — Why GLP-1s Might Reduce Nicotine Cravings

GLP-1 receptor agonists were not designed as cessation drugs. The cessation effect appears to emerge through several pathways.

Central reward circuit modulation. GLP-1 receptors are expressed in brain regions central to addiction — the ventral tegmental area, nucleus accumbens, and prefrontal cortex. Activating these receptors with peripheral GLP-1 agonists appears to modulate dopamine release in response to addictive stimuli, dampening the reward signal that drives compulsive nicotine use.

Appetite-and-craving overlap. The same brain circuitry that drives food craving overlaps substantially with the circuitry that drives nicotine craving. GLP-1s’ well-established appetite-suppressing effect appears to extend to nicotine craving in some users — they report not just eating less but also wanting nicotine less.

Stress and impulsivity effects. GLP-1 agonism appears to reduce stress-driven impulsivity in animal models, which translates to reduced relapse risk in cessation contexts where stress triggers are the dominant relapse driver.

Weight gain prevention. Post-cessation weight gain is a leading cause of relapse — many users restart nicotine specifically to manage weight after a quit attempt. GLP-1s prevent or reverse weight gain, removing a major relapse pressure. The NCT-registered 177-person RCT specifically tests this mechanism.

For the broader weight-and-cessation context, see our quit vaping without gaining weight and nicotine metabolism weight gain guides.

Which GLP-1s Are Being Studied

The trial portfolio centers on three molecules.

Semaglutide (Ozempic, Wegovy). The most-studied molecule for cessation as of 2026. Weekly subcutaneous injection. Marketed for diabetes (Ozempic) and obesity (Wegovy). The dose ranges in cessation trials match the obesity dose (up to 2.4 mg weekly), not the diabetes dose.

Tirzepatide (Mounjaro, Zepbound). Dual GIP/GLP-1 agonist with stronger effect on both glucose control and weight loss than semaglutide. Cessation trial data is currently smaller than for semaglutide but the case for similar or stronger cessation effect is strong on mechanistic grounds. Active trials are recruiting.

Liraglutide (Victoza, Saxenda). Daily injection rather than weekly. Older GLP-1 with smaller weight-loss effect than semaglutide. Some cessation trial data; not as actively researched in 2026 because newer molecules are better candidates.

Exenatide (Byetta, Bydureon). Twice-daily or weekly injection. Some early cessation trials. Less active research in 2026.

Off-Label Use — Where the Landscape Currently Sits

Because no GLP-1 is FDA-approved for cessation, prescribing for that indication is off-label. The off-label landscape splits into several categories.

Patients with established GLP-1 prescriptions for diabetes or obesity can discuss with their prescriber whether the cessation effect is a relevant benefit to track. The drug is already indicated, the cessation upside is a side benefit, and the risk profile is unchanged from the primary indication. This is the lowest-friction scenario.

Patients without an established GLP-1 prescription face a more complicated decision. Off-label use specifically for cessation is uncommon in routine clinical practice because the evidence base is not yet at the level that supports broad recommendation, insurance won’t pay for off-label cessation use, and the cash price is high ($800-1,200/month at U.S. retail for branded versions in 2026).

Compounded GLP-1 access is in flux. Compounding pharmacies stepped in during the 2023-2024 semaglutide shortage, but as of 2026, the FDA has substantially restricted compounded GLP-1 availability with the resolution of the shortage. Users considering compounded products should verify pharmacy legitimacy, sterility certification, and source materials carefully.

How GLP-1s Compare to Established Cessation Drugs

Comparison against the established options is useful for context. For the broader comparison set, see our Chantix alternatives guide.

vs. Varenicline (Chantix): Varenicline has a much larger evidence base for cessation (continuous abstinence rates of 25-35% at 6 months) and is FDA-approved for the indication. GLP-1s don’t yet have comparable cessation efficacy data. For users without a separate indication for GLP-1, varenicline is currently the higher-confidence prescription choice. See cytisinicline vs Chantix and generic varenicline vs Chantix for the varenicline landscape.

vs. Bupropion (Wellbutrin, Zyban): Bupropion is FDA-approved for cessation with continuous abstinence rates of approximately 20-25%. GLP-1s don’t have cessation efficacy data at this level. See quit vaping with bupropion.

vs. Cytisinicline (pending FDA approval June 20, 2026): Cytisinicline is the imminent new approval with continuous abstinence rates of 30-32% at week 24 in Phase 3 trials and a meaningfully better side effect profile than varenicline. See our cytisinicline launch prep checklist, cytisinicline availability timeline, and cytisinicline guides.

vs. NRT (patches, gum, lozenges, pouches): NRT is the lowest-cost, broadest-evidence baseline. GLP-1s and NRT have different mechanisms and are not mutually exclusive. For patients with established GLP-1 prescriptions, layering NRT on top during the active quit window is straightforward.

Side Effect Profile — What to Watch For

GLP-1 side effects relevant to cessation users:

Gastrointestinal: Nausea (15-44% of users in trials, higher at dose escalation), vomiting, constipation, diarrhea. These typically resolve over 8-12 weeks of consistent use but make the early quit window harder.

Hypoglycemia: Real risk in patients with diabetes on insulin or sulfonylureas; minimal risk in non-diabetic users.

Pancreatitis: Rare but documented; warning signal is sudden severe upper abdominal pain.

Gallbladder disease: Increased risk of gallstones with rapid weight loss.

Mental health: Some signal from post-marketing surveillance regarding mood changes; the magnitude is currently debated and the clinical relevance for cessation users is unclear.

Muscle and bone loss: Substantial weight loss on GLP-1s includes some lean mass loss; combined with cessation-period reduced activity, this can be meaningful for older users.

When GLP-1s Make Sense — and When They Don’t

Makes sense:

• Patient already on a GLP-1 for diabetes or obesity who wants to quit
• Patient with type 2 diabetes and Fagerström score ≥4 (the NCT-registered population)
• Patient with significant post-cessation weight gain risk who has failed prior quit attempts due to weight rebound
• Patient who has failed varenicline, bupropion, and combination NRT and is willing to consider off-label options

Doesn’t make sense:

• First-time quit attempt patient who hasn’t tried established options
• Patient without a separate GLP-1 indication facing $800-1,200/month cash price
• Patient with eating disorder history, particularly restrictive patterns
• Patient with pancreatitis or significant gallbladder disease history

Frequently Asked Questions

Does Ozempic help you quit vaping?

Possibly — published 2026 research suggests semaglutide reduces nicotine cravings and consumption through central reward-circuit modulation, but no Phase 3 trials of semaglutide specifically for vaping cessation have been published. The strongest case is in users already on Ozempic or Wegovy for diabetes or obesity, where the cessation effect becomes a side benefit. Off-label use specifically for vaping cessation is uncommon because the evidence base isn’t yet at the level supporting broad recommendation.

What GLP-1 is best for quitting smoking or vaping?

Semaglutide (Ozempic, Wegovy) is the most-studied option in 2026. Tirzepatide (Mounjaro, Zepbound) is mechanistically promising and being studied actively. Liraglutide has older data. For users with established GLP-1 prescriptions, the right answer is the molecule they’re already on — switching molecules specifically for cessation isn’t supported by current evidence.

Can I take Wegovy and Chantix together?

There’s no published evidence of clinically meaningful interaction between semaglutide and varenicline. They work through different mechanisms and could in principle be combined, but the combination isn’t a standard protocol and the evidence base for added cessation benefit over varenicline alone is not established. Discuss with a prescriber before combining.

How long does it take for Ozempic to reduce nicotine cravings?

Trial data suggests craving effects emerge within 2-4 weeks of starting semaglutide and continue to develop over 8-12 weeks as the dose escalates. The cessation timeline overlaps with the established weight-loss timeline. Don’t expect immediate craving suppression on day 1.

Will insurance cover GLP-1 for quitting vaping?

Almost certainly not in 2026. No GLP-1 is FDA-approved for nicotine cessation, and insurers don’t reimburse for off-label cessation use of these drugs. Coverage exists for diabetes (Ozempic, Mounjaro) and for obesity in many plans (Wegovy, Zepbound) — if the patient meets criteria for one of those primary indications, coverage flows from there and the cessation benefit is a side effect of an already-covered prescription.